Select Drug Profiles

F. Randy Vogenberg, PhD; John Santilli, MBA

Perspectives

James L. Mulshine, MD, David F. Yankelevitz, MD, Bruce S. Pyenson, FSA, MAAA

James L. Mulshine, MD; David F. Yankelevitz, MD; Bruce Pyenson, FSA, MAAA

Perspectives

Thinking About 2030

David B. Nash, MD, MBA

Original Research, Pain

Insights from Real-World Analysis of Treatment Patterns in Patients with Newly Diagnosed Knee Osteoarthritis

Stan Dysart, MD, MBA, Karina Utkina, PharmD, Laura Stong, PhD, Winnie Nelson, PharmD, MS, MBA, Naomi C. Sacks, PhD, Bridget Healey, MPH, Faizan Niazi, PharmD

Stan Dysart, MD, MBA; Karina Utkina, PharmD; Laura Stong, PhD; Winnie Nelson, PharmD, MS, MBA; Naomi Sacks, PhD; Bridget Healey, MPH; Faizan Niazi, PharmD

Original Research, Cardiometabolic Health

Clinical Pharmacist Outreach to Increase Statin Use for Patients with Cardiovascular Disease in a Safety-Net Healthcare System

Paul Cornelison, PharmD, Joel C. Marrs, PharmD, MPH, Sarah L. Anderson, PharmD, FCCP, BCPS, BCACP

Paul Cornelison, PharmD; Joel C. Marrs, PharmD, MPH; Sarah L. Anderson, PharmD

Original Research, Practice Management

Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies

Samantha Tomicki, MPH, Gabriela Dieguez, FSA, MAAA, Helen Latimer, MPH, Paul Cockrum, PharmD, George Kim, MD

Samantha Tomicki, MPH; Gabriela Dieguez, FSA, MAAA; Helen Latimer, MPH; Paul Cockrum, PharmD; George Kim, MD

FDA Approvals

Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker

FDA Approvals

Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations

FDA Approvals

Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation

FDA Approvals

Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma

Page 22 of 244
Results 211 - 220 of 2434

Select Drug Profiles

Subscribe Today!

I'd like to receive: